Genomagnetic LAMP-based electrochemical test for determination of high-risk HPV16 and HPV18 in clinical samples Martin Bartosik a, * , Ludmila Jirakova a , Milan Anton b , Borivoj Vojtesek a , Roman Hrstka a a Regional Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic b Dept. Obstet. Gynecol., Univ. Hosp. Brno and Medical Faculty Masaryk University, Obilni trh 11, 602 00, Brno, Czech Republic highlights graphical abstract  Electrochemical assay based on LAMP amplification for detection of two most oncogenic types, HPV16 and HPV18.  Good specificity, sensitivity and sta- bility was obtained.  Assay was successfully tested both on HPV16 and HPV18-positive patient samples, as well as HPV-negative samples. article info Article history: Received 11 May 2018 Received in revised form 6 August 2018 Accepted 10 August 2018 Available online xxx Keywords: HPV Cervical cancer Genomagnetic assay Electrode chip LAMP amplification abstract Major cause of cervical cancer is a persistent infection with high-risk types of human papillomaviruses (HPV). For that reason, HPV testing is now becoming an important addition to standard cytological screening of cervical malignancies in women (known as Pap test). New methods are sought which could offer rapid and inexpensive detection schemes, such as those based on electrochemical (EC) readout. Here, we developed an assay for parallel detection of two most oncogenic high-risk HPV types, HPV16 and HPV18, by combining loop-mediated amplification (LAMP) of template DNA, its separation using magnetic beads and detection with amperometry at carbon-based electrode chips. Our EC-LAMP test enabled us to successfully discriminate both HPV types not only in cancer cell lines, but also using clinical material obtained from HPV-positive patient samples. © 2018 Elsevier B.V. All rights reserved. 1. Introduction Infection with human papillomaviruses (HPVs) is very common, often cleared by the immune system without serious consequences. However, small fraction of infections becomes persistent over longer period of time and is associated with increased risk of developing precancerous lesions, and ultimately cancer (particularly cervical cancer in women). The traditional test for early detection of cervical cancer is the Pap test, a cytological ex- amination detecting potentially precancerous changes in the cer- vix. Persistent infections are caused by a small subset of HPVs, so- called high-risk HPVs. The most common high-risk types are HPV16 and HPV18, together accounting for over 70% of all cervical carcinomas [1]. Based on these findings, recent years witnessed increased efforts to develop and implement HPV testing as a screening option besides the standard cytological examination [2]. In fact, results from a large clinical trial ATHENA suggested that the * Corresponding author. E-mail address: martin.bartosik@mou.cz (M. Bartosik). Contents lists available at ScienceDirect Analytica Chimica Acta journal homepage: www.elsevier.com/locate/aca https://doi.org/10.1016/j.aca.2018.08.020 0003-2670/© 2018 Elsevier B.V. All rights reserved. Analytica Chimica Acta xxx (2018) 1e7 Please cite this article in press as: M. Bartosik, et al., Genomagnetic LAMP-based electrochemical test for determination of high-risk HPV16 and HPV18 in clinical samples, Analytica Chimica Acta(2018), https://doi.org/10.1016/j.aca.2018.08.020